Basic and clinical studies on grepafloxacin in the urological fiel

Tadasu Takenaka, Toyohiko Watanabe, Kohji Sakuramoto, Toshihide Hayashi, Kazuhiro Hata, Noriaki Ono, Hiromi Kumon, Hiroyuki Ohmori, Yasuhiro Katayama, Akihiro Mizuno, Mikio Kishi, Ryoji Nasu

Research output: Contribution to journalArticlepeer-review


We studied the antibacterial activity and clinical usefulness of grepafloxacin (GPFX), a new quinolone, in the urological field. 1) Antibacterial activity: The MICs of GPFX were measured against 210 clinical isolates of 14 species from urinary tract infection and compared with those of ofloxacin (OFLX), ciprofloxacin (CPFX) and norfloxacin (NFLX). In general, the antibacterial activity of GPFX was inferior to CPFX, but equal or superior to those of other control drugs. 2) Clinical efficacy: Although the clinical efficacy in acute uncomplicated cystitis and chronic bacterial prostatitis was good, the overall clinical efficacy rate according to the criteria of the UTI Committee was 36.4%(8/22) in chronic complicated UTI. Fifteen of 25 (60%) strains isolated were eradicated. 3) Side effects: Temporary discomfort of the left side of the body was observed in one case. Mild elevation of eosinophils or GOT·GPT was observed in one case.

Original languageEnglish
Pages (from-to)397-404
Number of pages8
JournalJapanese Journal of Chemotherapy
Publication statusPublished - Jan 1 1995


  • grepafloxacin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Basic and clinical studies on grepafloxacin in the urological fiel'. Together they form a unique fingerprint.

Cite this